Stephanie Head is a Technology Licensing Associate at MIT’s Technology Licensing Office. In her role, she assists with intellectual property and licensing matters, facilitating the transfer of technologies from the lab to the marketplace. She is also a J.D. Candidate at Suffolk University Law School and a graduate of Northwestern University where she obtained her Master of Science degree.
In 2024, WIPO and Italy’s Luiss Business School (LBS) established Global INTAN-Invest, a database that measures the growing interest and investment in intangible assets. These results, released annually via the World Intangible Investment Highlights, emphasize the importance of intangible assets and evaluate how companies can optimize their investments for competitive advantages.
In a significant ruling, the United States District Court for the District of New Jersey has ordered that Teva’s inhaler patents were improperly listed in the Food and Drug Administration’s (FDA) Orange Book, supporting Amneal’s claims that the patents did not cover key drug formulations. The case is centered around Teva’s New Drug Application (NDA) for the ProAir HFA inhaler.